£18.45
0.65% today
London, Oct 03, 05:35 pm CET
ISIN
GB00B0LCW083
Symbol
HIK

Hikma Pharmaceuticals Target price 2025 - Analyst rating & recommendation

Hikma Pharmaceuticals Classifications & Recommendation:

Buy
80%
Hold
20%

Hikma Pharmaceuticals Price Target

Target Price £26.19
Price £18.45
Potential
Number of Estimates 15
15 Analysts have issued a price target Hikma Pharmaceuticals 2026 . The average Hikma Pharmaceuticals target price is £26.19. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 20 analysts: 16 Analysts recommend Hikma Pharmaceuticals to buy, 4 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Hikma Pharmaceuticals stock has an average upside potential 2026 of . Most analysts recommend the Hikma Pharmaceuticals stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2030

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Billion £ 2.35 2.55
9.77% 8.40%
EBITDA Margin 22.85% 26.27%
7.49% 14.99%

14 Analysts have issued a sales forecast Hikma Pharmaceuticals 2025 . The average Hikma Pharmaceuticals sales estimate is

£2.5b
Unlock
. This is
5.46% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
£2.6b 8.48%
Unlock
, the lowest is
£2.4b 0.71%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 £2.3b 9.77%
2025
£2.5b 8.40%
Unlock
2026
£2.7b 5.20%
Unlock
2027
£2.8b 6.25%
Unlock
2028
£3.0b 6.75%
Unlock
2029
£3.2b 6.42%
Unlock
2030
£3.5b 7.71%
Unlock

14 Analysts have issued an Hikma Pharmaceuticals EBITDA forecast 2025. The average Hikma Pharmaceuticals EBITDA estimate is

£669m
Unlock
. This is
29.69% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
£747m 44.88%
Unlock
, the lowest is
£602m 16.66%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 £536m 1.55%
2025
£669m 24.65%
Unlock
2026
£717m 7.29%
Unlock
2027
£788m 9.82%
Unlock
2028
£835m 5.95%
Unlock
2029
£903m 8.11%
Unlock
2030
£994m 10.14%
Unlock

EBITDA Margin

2024 22.85% 7.49%
2025
26.27% 14.99%
Unlock
2026
26.79% 1.98%
Unlock
2027
27.69% 3.36%
Unlock
2028
27.49% 0.72%
Unlock
2029
27.92% 1.56%
Unlock
2030
28.55% 2.26%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2030

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share £ 1.20 1.74
87.50% 45.00%
P/E 10.55

14 Analysts have issued a Hikma Pharmaceuticals forecast for earnings per share. The average Hikma Pharmaceuticals EPS is

£1.74
Unlock
. This is
40.32% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
£1.84 48.39%
Unlock
, the lowest is
£1.58 27.42%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 £1.20 87.50%
2025
£1.74 45.00%
Unlock
2026
£1.93 10.92%
Unlock
2027
£2.15 11.40%
Unlock
2028
£2.37 10.23%
Unlock
2029
£2.67 12.66%
Unlock
2030
£3.01 12.73%
Unlock

P/E ratio

Current 14.78 24.63%
2025
10.55 28.63%
Unlock
2026
9.51 9.86%
Unlock
2027
8.54 10.20%
Unlock
2028
7.74 9.37%
Unlock
2029
6.85 11.50%
Unlock
2030
6.09 11.09%
Unlock

Current Hikma Pharmaceuticals Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Deutsche
Locked
Locked
Locked Aug 12 2025
JP Morgan Cazenove
Locked
Locked
Locked Aug 08 2025
Jefferies
Locked
Locked
Locked Aug 07 2025
Berenberg Bank
Locked
Locked
Locked Mar 10 2025
JP Morgan Cazenove
Locked
Locked
Locked Mar 07 2025
Berenberg Bank
Locked
Locked
Locked Jan 29 2025
Analyst Rating Date
Locked
Deutsche:
Locked
Locked
Aug 12 2025
Locked
JP Morgan Cazenove:
Locked
Locked
Aug 08 2025
Locked
Jefferies:
Locked
Locked
Aug 07 2025
Locked
Berenberg Bank:
Locked
Locked
Mar 10 2025
Locked
JP Morgan Cazenove:
Locked
Locked
Mar 07 2025
Locked
Berenberg Bank:
Locked
Locked
Jan 29 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today